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Purpose: This study sought to determine the maximum tolerated dose (MTD) of oral etoposide in combination
with radiotherapy in head and neck squamous cell carcinoma (HNSCC).
Patients and Methods: Phase I, multicenter, open-labelled, non-comparative and dose escalating trial. Patients
with locally advanced HNSCC were enrolled onto cohorts of escalating dose of etoposide. Oral etoposide was
administered on five consecutive days every week for 7 weeks (7 treatment cycles) in combination with daily
radiotherapy (70 Gy /35 fractions). Two dose levels (25 mg/day and 50 mg/day) of etoposide were planned and
three to six patients were to be enrolled at each level according to the potential DLTs.
Results: Fourteen patients were allocated to two dose levels: 25 mg/day (3) and 50 mg/day (11). Cisplatin was
contra-indicated in all the patients included. Only one patient (50 mg/day) presents a grade 4 neutropenia (DLT),
no other DLTs were observed. The most frequently adverse events (AEs) were radiomucositis. Two deaths before 3
months of end of treatment were not related to treatment. Seven patients were still alive with a median follow-up
of 30 months (12–58 months). Nine patients had a complete response (CR) at 3 months after the radiotherapy;
Among the 9 patients, 3 patients had a local relapse; one patient with local and distant relapse.
Conclusion: Due to only one DLT experienced, it is possible to a dose of 50 mg/day for phase II studies, however
this should be considered with caution.
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Treatment of inoperable locally advanced head and neck
squamous cell carcinomas (HNSCC) is based on radio-
therapy (RT) delivering 70 Gy/ 7 weeks. Chemotherapy
is an integral part of the treatment of locally advanced
HNSCC, while added to radiotherapy [1]. Concurrent
chemo-radiotherapy (CRT) has become a standard treat-
ment of locally advanced HNSCC, as reported in the
Meta-Analysis of Chemotherapy in Head & Neck Cancer
(MACH-NC). A recent update has demonstrated an abso-
lute survival benefit of 6.5% at 5 years in favour of adding
concurrent chemotherapy to RT [2]. The gain of survival
reaches 11% at 5 years when chemotherapy is cisplatin* Correspondence: jean.bourhis@igr.fr
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reproduction in any medium, provided the oralone in combination with RT. In a randomized phase III
trial GORTEC 94–01, we showed the superiority of concur-
rent CRT (carboplatin and 5FU with RT 70 Gy/ 7 weeks)
compared with RT alone in tumor control. However, these
improvements in tumor control were accompanied by an
increase of acute toxicity (hematologic, mucositis etc.),
and also of late toxicity [3]. It is therefore essential to
optimize these associations of CRT for more effective
and less toxic effects.
The rationale for the chemo-radiotherapeutic combina-
tions relies on spatial cooperation or interaction between
modalities [4]. Interactions may take place at the molecular
level, with altered DNA repair or modification of the lesions
induced by drugs or radiation; at the cellular level, notably
through cytokinetic cooperation arising from differential
sensitivity of the various compartments of the cell cycle to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reoxygenation, increased drug uptake or inhibition of
repopulation or angiogenesis [4]. Many chemotherapeutic
agents have demonstrated a radiosensitizing effect [5,6].
Among the drugs potentially interesting in the context of
these optimizations, etoposide (VP-16, CelltopW) is of
particular interest. The topoisomerase inhibitor etoposide is
a semisynthetic derivate of epipodophyllotoxin which has
proven activity in several malignant diseases and is com-
monly used for treating germ cell tumors, haematological
malignancies, and small cell lung cancer [7]. Etoposide has
been found to act as a radiosensitizer and is able to potenti-
ate the effect of irradiation when used in experimental
models [6]. Moreover, it is possible to use etoposide orally,
thus limiting practical difficulties related to the administra-
tion of drugs (no hospitalization, hydration etc.). However,
the tolerability of combination of concurrent oral etoposide
and radiotherapy are poorly understood.
The latest pharmacokinetic data showed that the clinical
effects observed with oral etoposide vary depending on
the dose and especially the splitting of the dose. Thus the
toxicity was much reduced by administration of 75 mg
divided in 3 doses of 25 mg, compared with a single dose
of 75 mg which was responsible for a high serum peak
and significantly higher toxicity. When used in association
with radiotherapy, it is possible that the divided dose of
etoposide is a factor in determining the tolerance of
combined treatment.
The aim of the study was to evaluate the feasibility
and dose-limiting toxicity (DLT) of the combination of
radiotherapy and oral administration of etoposide in
patients with locally advanced HNSCC. The principal
objective was to evaluate the DLT and to determinate
the level of maximum tolerated dose (MTD) and the
secondary objective was to evaluate the overall survival
and loco-regional control rate.
Methods
Study design
This open-label, non-comparative, dose-escalation study
was conducted in two centers in France with approval of
Kremlin-Bicêtre Ethics Committee (France). Seven cycles
of CelltopW were administered on five consecutive days/
week, in conjunction with continuous conventional
radiotherapy. Two dose levels (25 mg/day and 50 mg/day)
of CelltopW were planned in order to recruit patients
according to the potential DLTs experienced. Etoposide
was delivered orally in two groups: 25 mg/day (1 capsule of
CelltopW 25 mg administrated orally 2 hours before daily
irradiation); 50 mg/day (2 capsules of CelltopW 25 mg or 1
capsule of CelltopW 50 mg administrated orally).
Dose escalation was considered when the last patients
receiving the inferior dose level had completed the
treatment plus 2 weeks follow-up. Patients were initiallyenrolled at the first dosing level of 25 mg/day and the
second dosing group of 50 mg/day was further planned
providing the maximum tolerated dose (MTD) was not
reached. At least three patients were included in each dose
level. Capsules containing 25 mg or 50 mg of CelltopW
were administered to patients and taken orally daily over
five consecutive days, every week for seven weeks
(seven cycles). Assignment of patients to each dose
level was centralized (2 centres participating) in order
to ensure that an adequate number of patients had
completed the necessary dose level and the assessment
of toxicity before escalating to the next dose level.
Three to six patients were to be enrolled at each dose
level according to the occurrence of DLTs. At the second
dose level, in the absence of DLTs, additional 5 patients
were to be enrolled to confirm that the MTD was reached.
Definition of the occurrence of DLTs: All Grade 3–4
toxicities (NCI Common Toxicity Criteria, version 3)
were considered as DLTs, except for: grade 3–4
mucositis toxicity was expected during combined
radiation-chemotherapy; grade 3 dermatitis was not
considered as DLT; hematologic toxicity (grade 3
thrombocytopenia / non-febrile grade 3 neutropenia).
CelltopW dose escalation was determined by the number
of patients experiencing Dose Limiting Toxicities (DLTs)
in order to elucidate the MTD. A MTD was defined as
the dose of CelltopW in combination with radiotherapy in
which more than 1 of 6 patients presented a DLT.
The laboratory tests (haematology and biochemistry)
were performed at screening and once a week during
the treatment period and at each visit of the follow-up
period, similarly, performance status was also assessed at
every time-point.
Patients
Before being enrolled in the study, written informed consent
was obtained from each patient. The main eligibility criteria
were: T1-T4 N0-N3 corresponding to stage III or IV (UICC
2002) or T0 only if N2-N3, oropharynx, hypopharynx, lar-
ynx or oral cavity non-operated histologically proved squa-
mous cell carcinoma; Age more than 20 years; Karnofsky
performance status > = 70; not amenable to a combined
radiation and surgery because of the loco-regional extension
and / or general medical state; Laboratory tests compatible
with the chemotherapy (platelet count >150 000/μl,
neutrophiles > 2000/μl, creatinine serum level < 130 μmol/l
and SGOT, SGPT, alkaline phosphatase, bilirubin less than
two and a half times normal). All patients were required to
sign the informed consent document that was approved by
each Institutional Review Board before initiating protocol
therapy. A patient was considered unsuitable for inclusion
in case of: previous RT or chemotherapy; infection; bulky
lymph node (> 6 cm, N3) is not recommended, but will be
left to the discretion of each investigator.
Table 1 Patient demographics








Chronic cardiac disease 7 (50)








Oral cavity 2 (15)
Table 2 TNM staging
T1 T2 T3 T4 Total
N0 0 0 1 3 4
N1 1 1 1 1 4
N2a 0 0 1 0 1
N2b 2 1 0 0 3
N2c 0 0 0 0 0
N3 0 0 2 0 2
Total 3 2 5 4 14
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general clinical examination; a local and regional tumour
staging; an assessment of tumor spread and second location
research (head and neck, bronchus, oesophagus) by a pan
endoscopic examination under general anesthesia; CT
and / or MRI; chest X-ray and liver ultrasound; according
to the clinical context, bone scan and / or PET Scan; other
complementary examinations; ECG as complete heart
work-up if necessary; blood cells count, electrolyte,
creatinine, calcium, glucose, alkaline phosphatase, bilirubin,
transaminases, prothrombin.
Radiotherapy
In conjunction with etoposide, patients received concomi-
tant radiotherapy 2 Gy/fraction, 5 fractions per week, up to
70 Gy in 35 fractions and seven weeks. Positive lymph
nodes received 64 to 70 Gy and prophylactic neck lymph
node levels were delivered to 50 Gy. Radiation was
delivered with 6 MV photon beams, using a conventional
treatment planning system or three-dimensional (3D)
conformal radiotherapy. Reproducible immobilization was
required. 3D treatment planning using CT-based tumor
and normal tissue definition was recommended.
Evaluation of response
Evaluation of response was carried out at 3 months after
the end of radiation and included physical examination, CT
or MRI of the head and neck and / or PET/CT. Complete
response was defined as a complete disappearance of
tumor. Partial response was defined as a decrease of 50% or
more in the sum of the products of diameters of all measur-
able lesions. Patients were followed every 3 months with
clinical examination and CT or MRI of the head and neck
and / or PET/CT in case of suspicion of relapse.
Results
Patient characteristics
Two dose levels (25 mg/day and 50 mg/day) of CelltopW
were used in this trial as initially planned. Three patients
were enrolled at the dose level of 25 mg/day. Three
patients were initially enrolled at the dose level 50 mg/day,
and 3 further patients were enrolled because of the
occurrence of one DLT, and then 5 additional patients were
enrolled in the second level for a confirmation of MTD. As
shown in Table 1, 14 patients were included and the major-
ity of patients were male (13/14) with a median age of 58
years (51–78 years), and 7/14 patients with chronic cardiac
disease (2 with myocardial infarctus, 3 with cardiomyop-
athy, 3 with heart failure), 4/14 patients with pulmonary
associated disease (2 with chronic obstructive pulmonary
disease, 1 with pulmonary embolism and 1 with respiratory
failure). Most patients were heavily tobacco-toxic and there
is also 1 patient with hypoacusia and 2 other patients with
stroke and diabetes. Cisplatin was contra-indicated in allthe patients included. The most frequent tumor site was
oropharynx (7 patients), and 2 patients with laryngeal
cancer, 3 with hypopharynx and 2 with oral cavity. All the
patients had a biopsy proven squamous cell carcinoma. All
had tumors staged as T2 to T4, N0 to N2c and M0
according to UICC 2002 classification (Table 2).
Treatment
Radiotherapy
All the included patients completed the planed irradiation
68–70 Gy except two patients, one at the dose level of 50
mg/day, stopped at 42.5 Gy and then died of pulmonary
emboli which was considered as not related with the RT-
CT; another patient, also at the dose level of 50 mg/day,
stopped at 10 Gy and died of cardiac disease. Among the
patients who completed the whole course radiotherapy, in
one patient at the dose level of 50 mg/day, the radiother-
apy had been interrupted more than one week (11 days)
because of febrile disease (there is no grade 3 neutropenia,
Table 3 Toxicity after CelltopW and radiation
25 mg/day 50 mg/day
Mucositis
Grade 1/2 3
Grade 3 3 7
Radiodermitis
Grade 1/2 3 6
Grade 3 4
Dysphagia
Grade 1/2 3 6
Grade 3 4
Leucopenia
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because of mucositis, and the interruption of 11 days is not
a continuous interruption and it is rather a mixed interrup-
tion with also machine maintenance and breakdown); in
another patient at the dose level of 50 mg/day, the
radiotherapy had been interrupted more than one week
(9 days) because of the breakdown of Linac.
Chemotherapy
One patient at the dose level of 50 mg/day completed 4
weeks of CelltopW with radiation and stopped at 42.5 Gy
and then died of pulmonary embolism; one patient at
the dose level of 50 mg/day had never taken the oral
CelltopW because of deglutition problem who died after
one week of radiotherapy (10 Gy); one patient at the dose
level 50 mg/day completed only 4 weeks CelltopW because
of febrile neutropenia (DLT see below), and another patient
in the same group completed a little less than 6 weeks of
CelltopW because of febrile reason (we did not find the
exact reason, probably because of mucositis without grade
3 neutropenia). All other 10 patients completed all the
planned 7 cycles of CelltopW.
Safety results
Only one patient experienced DLT (febrile grade 4
neutropenia) at the dose level of 50 mg/day at week 5.
Other severe AEs included grade 3 mucositis in 10
patients (3 patients at the dose level of 25 mg/day, 7
patients at the dose level of 50 mg/day). 4 patients at
the dose level of 50 mg/day suffered from grade 3
radiodermitis. Two patients with grade 3/4 leucopenia
were observed at the dose level of 50 mg/day. One patient
with grade 3 neutropenia was observed at the dose level
of 50 mg/day. 4 patients at the dose level of 50 mg/day
suffered from grade 3 dysphagia.
Grade 1 or 2 toxicities including grade 2 mucositis
in 3 patients at the dose level of 50 mg/day ; 6 patients
(2 patients at the dose level of 25 mg/day, 4 patients at
the dose level of 50 mg/day) suffered from grade 2
radiodermitis and 3 patients with grade 1 radiodermitis
(1 patient at the dose level of 25 mg/day and 2 patients at
the dose level of 50 mg/day 7 patients (3 patients at the
dose level of 25 mg/day, 4 patients at the dose level of
50 mg/day) suffered from grade 2 dysphagia and 2 patients
at the dose level of 50 mg/day with grade 1 dysphagia.
Six patients at the dose level of 50 mg/day had grade 1/ 2
anemia. One patient at the dose level of 50 mg/day had
grade 2 leucopenia, grade 1 neutropenia and thrombopenia;
one patient at the dose level of 50 mg/day with grade 2
neutropenia; One patient at the dose level of 25 mg/day
with grade 1 leucopenia. Two patients at the dose level of
50 mg/day had renal toxicity (creatininemia grade 1). Other
toxicities such as hepatic and neurological toxicities have
not been observed in the present study (Table 3).One patient with heavy antecedents (coronary heart
disease, hypertension and chronic obstructive pulmonary
disease) before CRT, at the dose level of 50 mg/day,
stopped at 42.5 Gy and then died of pulmonary embolism,
and another patient with a T3N3 laryngeal cancer at the
same dose level died of acute respiratory distress syndrome
with hemorrhagic event of loco-regional disease progres-
sion one month after the chemo-radiotherapy. One patient
had never taken CelltopW because of deglutition problem
and died after one week of radiotherapy at the dose level of
50 mg/day. All these three deaths had been considered as
in association with their intercurrent diseases and not with
etoposide and radiation.
Efficacy
Among the 12 patients who completed the whole course
of radiotherapy, one patient died of respiratory depresses
one month after the completion of radiotherapy at the
dose level of 50 mg/day. This is a patient with T3N3
laryngeal cancer and the cause of death is probably
respiratory depresses induced by hemorrhagic event of
loco-regional disease progression. Seven patients of the
11 evaluable patients were still alive with a median
follow-up of 30 months (12–58 months). Nine patients
had a tumoral complete response (CR) at 3 months after
the radiotherapy; one patient had a CR in the primary
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and then progression in mediastinal lymph nodes,
pulmonary and cerebral metastases; another patient had a
local progression (P) and presented a second oesophageal
cancer (Table 4). Among the 9 patients who had a CR at 3
months after radiotherapy, 3 patients had a local relapse;
one patient with a local relapse, bone metastasis and a
second oesophageal cancer; no other regional relapse
and distant metastasis. The causes of death of the four
patients were: three with loco-regional disease relapse
(including one patient with hemorrhagic local progression
at the end of treatment) and one with metastatic relapse.
Discussion
The meta-analysis MACH-NC demonstrated that concur-
rent chemo-radiotherapy allowed a significant survival
benefit compared to radiation alone and single agent cis-
platin appears to be one of the most efficient concurrent
treatment in combination with radiotherapy [2]. However,
the compliance to the most commonly used cisplatin
regimen (100 mg/m2, every 3 weeks [8]) is relatively poor
and the concurrent use of cisplatin and radiotherapy has
a relatively high toxicity causing adverse effects such as
hemato-, nephro-, neurotoxicity, gastrointestinal (GI) tox-
icity and severe oral mucositis, which make this treatment
suitable only for selected patients. The most frequently
reported dose-limiting factors with intravenous cisplatin
were renal, haematologic and mucositis toxicities. Bernier
et al. [8] showed that the rate of severe grade 3–4 mucositis
was 41%, severe leukopenia 16%, and severe vomiting
was observed in 11% of patients in a randomized study
(EORTC 22931).
The recent published results of 10 years follow-up of UK
Head and Neck (UKHAN1) trial including 966 patients
with LAHNC confirmed the benefit of concurrent CRT
which used either methotrexate alone, or vincristine,
bleomycin, methotrexate, and fluorouracil [9]. These
results suggest that other chemotherapeutic agents
have also shown comparable outcome than cisplatin.
Among them, etoposide provides a safe and convenient
alternative method of administration and has shown
activity in lung cancer, ovarian carcinoma, etc. [10].
Etoposide administered orally has been shown previously
to be as effective as intravenous etoposide with similar
serum half-life, renal clearance, volume of distribution, and
toxicity. Oral etoposide has been used in the treatment of
patients with various types of cancer with tolerable side
effects. Oral etoposide has been investigated as well in
patients with advanced head and neck cancer [11]. TheTable 4 Response to treatment
Response CR PR S P
Number patient (%) 9 (82%) 1 (9%) 0 1 (9%)palliative effect of oral etoposide has been assessed in
heavily pretreated patients with recurrent and/or metastatic
HNSCC and oral etoposid has been shown to be markedly
effective and an excellent tolerated therapy in this popula-
tion of severely disabled patients. Oral etoposide was very
well tolerated with alopecia and myelosuppression being
the most encountered toxicities [11].
Our present study showed the feasibility of combined
oral etoposide (25–50 mg/day for 7 cycles) with concur-
rent conventional radiotherapy with tolerable side effects
and comparable efficacy. All the 3 patients with CelltopW
25 mg/day well tolerated all the course of treatment; and
most of the 11 patients who received CelltopW 50 mg/day
(only one DLT and another patient with grade III
neutropenia). The observed mucositis and radiodermatitis
are comparable with other reports and all manageable. We
could recommend the dose 50 mg/day of CelltopW for use
in the future phase II trial. A recent study for HNSCC with
13–27 days of oral etoposide 50 mg/day combined with
hyperfractionated radiotherapy has shown similar findings
[12]. In our present study, we observed the same profile
of toxicities: mucositis and haematological toxicities,
however, the dose of etoposide used in our study is
higher (50 mg/day for 35 days) than that study (same
daily dose for 27 days). Moreover, many patients in our
present study presented chronic cardiac or pulmonary
co-morbidities and they were considered as not suitable
for platinum-based chemotherapy.
Targeted therapies have been shown interesting
radiosensitizing effect in the preclinical and clinical
setting [13-15]. EGFR inhibition has been shown its
efficiency in the treatment of head and neck cancer
these recent years with particularly limited toxicities
compared with platinum-base chemotherapy. Bonner, et al.
reported recently that treatment of advanced HNSCC
with concurrent radiotherapy plus cetuximab improves
locoregional control and reduces mortality without
increasing the common toxic effects associated with
radiotherapy [16,17]. Since then, cetuximab and radio-
therapy combination has become an alternative of
platinum-base concurrent chemo-radiotherapy. In fact,
our current trial has been designed and conducted
before the publication of results of Bonner’s trial.
One of the concerns of concurrent cetuximab and
radiotherapy is severe skin toxicities which have been
shown more and more frequently these last years
[18-21]. We should also keep in mind that infusion-
related complications occur in about 5% of the patients
treated with cetuximab [22]. In addition, cardiac toxicity
could also be a potential complication associated with
cetuximab, especially in patients with prior cardiac
comorbidities. Thus, cetuximab needs to be used with
caution in fragile patients especially in patients with
prior cardiac disease. In our present study, most of the
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which limited the use of conventional chemotherapy and
even cetuximab should be used cautiously. We obtained
a comparable overall survival even in this patient
population. We could conclude that concurrent radio-
therapy and oral etoposide 50 mg/day for 7 weeks
could be another alternative treatment for patients with
locally advanced HNSCC, especially for the patients
with chronic cardiac or pulmonary co-morbidities.
These recent years, HPV-related HNSCC especially
oropharyngeal cancer has been shown better survival
compared with HPV-non-related HNSCC [23-25]; thus,
one of the questions remain is whether other chemo-
therapeutic agents could obtain comparable disease
control as platinum and less toxicities when associated
with radiotherapy in HPV-related HNSCC.
Conclusions
In conclusion, the recommended dose of oral etoposide for
phase II trial in combination with radiotherapy could be
50 mg/day, on five consecutive days per week, during the
course of radiotherapy, however, this should be considered
with caution due to 2 deaths (not related to treatment)
before 3 months of the end of treatment.
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